Analysis of the difference between pemetinib/dabotan and seputinib

Pemigatinib and Selpercatinib are both targeted drugs that have attracted much attention in the field of cancer treatment in recent years. They have shown significant efficacy in the treatment of specific types of cancer. Although these two drugs have certain similarities in their mechanisms of action, their respective indications, target selection, and clinical applications are significantly different. Understanding these differences is especially important for doctors when formulating treatment plans.

Pemetinib is aFGFR inhibitor, that is, a Fibroblast Growth Factor Receptor (FGFR) inhibitor. FGFR plays a key role in the occurrence and development of various tumors, especially in cancers with some gene mutations or amplifications. Pemetinib inhibits multiple receptors such as FGFR1, FGFR2, and FGFR3, inhibiting the downstream signaling pathways activated by them, thereby preventing the proliferation and metastasis of tumor cells. Pemetinib is mainly used to treat cholangiocarcinoma with FGFR2 gene rearrangements or mutations, especially when other treatments are ineffective, showing good efficacy.

Seputinib is aRET inhibitor, mainly targeting tumors with RET gene mutations or fusions. RET (Rearranged during Transfection) is a proto-oncogene, and its abnormal fusion or mutation is common in non-small cell lung cancer (NSCLC), thyroid cancer, and some types of colorectal cancer. Seputinib prevents the proliferation and spread of tumor cells by inhibiting the activation of RET receptors. Unlike pemetinib, seputinib has a more specific target and only targets tumors containing RET gene abnormalities.

Pemetinib is currently approved for the treatment of cholangiocarcinoma (CCA), particularly those harboring FGFR2 gene rearrangements or mutations. Abnormalities in the FGFR2 gene are often associated with tumor aggressiveness and drug resistance. Pemetinib can effectively control tumor growth by inhibiting the overactivity of this receptor. Although it has shown good clinical effects in the treatment of cholangiocarcinoma, its indications are relatively narrow and are mainly concentrated in patient groups with specific gene mutations.

In contrast, seputinib is approved for treatmentRET mutation or RET gene fusion-positive non-small cell lung cancer and thyroid cancer. For these patients, abnormalities in the RET gene are often the driving factor for tumorigenesis. By targeting this gene abnormality, septinib significantly improves the prognosis of patients. In clinical application, seputinib has a relatively wider range of use, covering a variety of tumor types, especially in RET-mutated non-small cell lung cancer and thyroid cancer, showing strong therapeutic potential.

Pemetinib and seputinib have certain similarities in side effects, but there are also some differences. Common side effects of both drugs include fatigue, nausea, loss of appetite and other digestive system symptoms, which are consistent with the side effects of most targeted drugs. Side effects of pemetinib may also include visual disturbances and skin reactions, and patients may develop rashes or dryness due to its mechanism of inhibiting FGFR. In addition, pemetinib may cause liver damage, so liver function needs to be monitored regularly during use.

The side effects of Seputinib are more concentrated on gastrointestinal problems, such as diarrhea, vomiting, etc., and due to its targetingRET receptor, it may cause cardiovascular side effects such as hypertension and QT interval prolongation. Patients' cardiac function needs to be monitored, especially during treatment with seputinib. In comparison, the side effects of seputinib may be more concentrated on the cardiovascular system, and special attention needs to be paid to changes in electrocardiogram.

Reference materials:https://go.drugbank.com/drugs/DB15102